Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Dengue Vaccine Gets WHO Backing In People Previously Infected

Executive Summary

Label restriction, discussions with regulators should keep vaccine in use, Sanofi suggests; Philippines suspended its vaccination program after data showed product can worsen disease in those not previously exposed to infection.

Advertisement

Related Content

Sanofi's Dengvaxia Postmarket Monitoring Plan Targets Vaccine's Safety Concerns
Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up
Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?
Will Sanofi’s Dengvaxia Woes Spiral Beyond The Philippines?
Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival
Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival
Takeda's Dengue Vaccine Candidate Aims To Avoid Dengvaxia Problems
Sanofi's Dengue Vaccine Health Warning Seen Hitting Product's Sales
Takeda's Dengue Vaccine Still Promising, But Could Be A Niche Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel